Preclinical breakthroughs have paved the way for the development of a myriad of IDH-targeted therapies, including small molecule IDH inhibitors (directed against IDH1 and IDH2 mutations) and vaccines that elicit immunogenic responses against glioma cells with these mutations. This evidence concerns the gene IDH2 and glioma.